|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2.84 - 2.90|
|52 Week Range||1.93 - 3.55|
|PE Ratio (TTM)||6.60|
|Earnings Date||Feb 21, 2018 - Feb 28, 2018|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||3.50|
DUBLIN , Nov. 15, 2017 /PRNewswire/ -- Noden Pharma DAC, a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a broad range of therapeutic areas, announced ...
AstraZeneca (AZN) received CHMP recommendation for marketing approval of its pipeline candidate, benralizumab for treating severe eosinophilic asthma.
NEW YORK, Nov. 09, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tegna ...
INCLINE VILLAGE, Nev., Nov. 8, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDLI) reiterated that its proposal to acquire Neos Therapeutics, Inc. (NEOS) for $10.25 per share in cash will expire today at market close. PDL originally made public its proposal to acquire Neos on October 26, 2017 at a premium of approximately 40 percent to the pre-proposal closing price of Neos shares. PDL is confident its proposal represents fair value for the Company and offers certain and compelling value for Neos shareholders.
INCLINE VILLAGE, Nev. , Nov. 7, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , PDL's president and chief executive officer, will present at two ...
The Incline Village, Nevada-based company said it had profit of 14 cents per share. Earnings, adjusted for one-time gains and costs, came to 15 cents per share. The biotechnology company posted revenue ...
NEW YORK, NY / ACCESSWIRE / November 2, 2017 / PDL BioPharma, Inc. (NASDAQ: PDLI ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 2, 2017 at 4:30 PM Eastern ...
U.S. drugmaker Neos Therapeutics Inc , which this week rejected a fourth takeover offer by PDL Biopharma Inc, will consider offers from other potential buyers, according to people familiar with the matter. Neos, a developer of attention deficit disorder treatments, rejected, as inadequate, a nearly $300 million all-cash bid from PDL that was more than a 40 percent premium to its market value. PDL could clinch a deal if it were to offer a higher price, the sources added, cautioning that there was no certainty of any transaction.
INCLINE VILLAGE, Nev. , Oct. 30, 2017 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today issued the following statement in response to the Neos Therapeutics, ...
Shares of Neos Therapeutics Inc. sank 3.5% in premarket trade Monday, after the company said it rejected PDL BioPharma Inc.'s unsolicited buyout bid. The drug maker said PDL's proposal to buy Neos for ...
DALLAS and FORT WORTH, Texas, Oct. 30, 2017 /PRNewswire/ -- Neos Therapeutics, Inc. (NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technologies, today announced that its Board of Directors has unanimously rejected the October 26 unsolicited proposal from PDL BioPharma, Inc. (PDLI) to acquire all of the outstanding shares of Neos for $10.25 per share in cash. Neos noted that PDL's October proposal is identical in all material respects to proposals received in June, July and September from PDL, which were also reviewed and unanimously rejected by the Neos Board. After a comprehensive review, conducted in consultation with its financial and legal advisors, the Neos Board affirmed its previous determinations that PDL's proposal undervalues Neos, does not reflect Neos' strategic value and future prospects for continued growth and value creation, and is not in the best interests of the Company or Neos shareholders.
INCLINE VILLAGE, Nevada, Oct. 30, 2017 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (PDLI) today announced that on October 27, 2017, PDL and Depomed, Inc. ("Depomed") entered into a settlement agreement with Valeant Pharmaceuticals International, Inc. and its indirect subsidiary Valeant Pharmaceuticals Luxembourg S.à r.l.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives PDL BioPharma, Inc. a score of 53. Our analysis is based on comparing PDL BioPharma, Inc. with the following peers – Compugen Ltd., Nektar Therapeutics, BioTime, Inc., Mylan N.V., Amgen Inc., Eli Lilly and Company, Enzon Pharmaceuticals, Inc. and Sangamo Therapeutics, Inc. (CGEN-US, NKTR-US, BTX-US, MYL-US, AMGN-US, ... Read more (Read more...)
Neos Therapeutics Inc (NASDAQ:NEOS) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 37% upturn. The reason? PDL BioPharma (NASDAQ:PDLI) made a hostile bid to acquire Neos for $10.25 share in cash (40% upside from yesterday's close). PDL first formally proposed to acquire Neos on June 23, 2017, but Neos' board rejected the offer.
Pharmaceutical company Neos received an offer for $10.25 per share, which would value the deal around $288 million. It's the third time PDL has tried to make a deal.
Shares of Neos Therapeutics Inc. rocketed 42% in morning trade Thursday, after the pharmaceutical company confirmed the receipt of an unsolicited buyout bid by PDL BioPharma Inc. for $10.25 a share, and ...
DALLAS and FORT WORTH, Texas, Oct. 26, 2017 /PRNewswire/ -- Neos Therapeutics, Inc. (NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technologies, today confirmed that it has received an unsolicited proposal from PDL BioPharma, Inc. (PDLI) to acquire all of the outstanding shares of Neos for $10.25 per share in cash. Consistent with its fiduciary duties and in consultation with its independent legal and financial advisors, the Neos Board of Directors will carefully review and consider the PDL proposal to determine the course of action that it believes is in the best interest of the Company and Neos shareholders.
PDL BioPharma Inc. announced Thursday an unsolicited proposal to buy Neos Therapeutics Inc. in a cash deal that would value Neos at about $288 million. PDL said it would pay $10.25 for each Neos share ...
INCLINE VILLAGE, Nev., Oct. 26, 2017 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (PDLI) today announced that it has submitted a proposal to acquire Neos Therapeutics, Inc. ("Neos") (NEOS) for $10.25 per share in cash. This all-cash transaction represents a premium of 40% to the closing price of Neos shares on October 25, 2017 and a premium of 41% to Neos' share price prior to PDL's initial proposal on June 23, 2017.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for PDL BioPharma, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to PDL BioPharma, Inc. Here are 5 ETFs with the largest exposure to PDLI-US. Comparing the performance and risk of PDL BioPharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)